Linklaters (Brussels)

Gerwin Van Gerven

Linklaters (Brussels)
Lawyer (Partner)

Gerwin Van Gerven has over 25 years’ experience advising major corporates and investment firms on competition law. He is widely respected as a highly skilled European competition lawyer, advising on complex competition issues, including on merger control, anti-cartel enforcement, monopolisation cases and other conduct investigations. He represents clients from around the world in proceedings before the European Commission, the European Court of First Instance and the European Court of Justice, courts and competition authorities across. Gerwin’s experience spans many industry sectors, with recent experience in telecoms and information technology, healthcare, consumer goods, retail and energy. He has advised on several of the major merger investigations of the last twenty years, including in around twenty ‘Phase II’- investigations conducted by the European Commission. Gerwin is regarded as one of the leading competition lawyers of his generation. Since many years, he has been ranked consistently amongst the top ten competition lawyers in the world in all major directories.


Auteurs associés

Linklaters (Düsseldorf)
Linklaters (London)
Linklaters (London)
Linklaters (Beijing)
Linklaters (Paris)


2943 Bulletin

Christopher Bellamy KC, Dario Dagostino, Gerwin Van Gerven The EU Court of Justice confirms that legal professional privilege under EU law does not extend to communications with in-house lawyers (Akzo Nobel)


Background In February 2003, the Commission, with the assistance of the UK’s Office of Fair Trading, conducted a dawn raid at the UK premises of Akzo Nobel and Akcros Chemicals on suspicion of possible anti-competitive practices. During the raid, a dispute arose between the investigation (...)

Anne Wachsmann, Christopher Bellamy KC, Gerwin Van Gerven, Jeffrey Schmidt, Olivier d’Ormesson, Robert Gavin The EU Court of Justice confirms that the Commission must assess whether an agreement to limit parallel trade in medicines has pro-competitive benefits (GlaxoSmithKline)


On 6 October, the European Court of Justice (‘ECJ’) issued another “score draw” judgment in the long-running battle of R&D-based pharmaceutical companies to limit parallel trade in medicines across the EU. While the ECJ required the European Commission to conduct an in-depth examination of (...)

Anne Wachsmann, Christopher Bellamy KC, Gerwin Van Gerven, Jonas Koponen, Joseph Armao, Nicole Kar, Olivier d’Ormesson The EU Commission introduces a new settlement procedure for cartel cases during investigations


On 30 June 2008, the European Commission introduced a new settlement procedure for cartel cases. Under the new procedure, the parties in a cartel investigation may acknowledge their breach of European antitrust law and waive certain procedural rights in exchange for a 10% reduction of the (...)


Total des visites

Nombre de lectures par contribution

Nombre de contributions

Classement de l'auteur
En nombre de contributions
En nombre total de visites
En nombre moyen de visites
Envoyer un message